CLINICAL TRIAL SUMMARY

MDACC Study No:RTOG0848 (clinicaltrials.gov NCT No: NCT01013649)
Title:A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Principal Investigator:Christopher H. Crane
Treatment Agent:Capecitabine; Erlotinib; Gemcitabine
Study Status:Terminated
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Gastrointestinal
Phase of Study:Phase III
Treatment Agents:Capecitabine
Erlotinib
Gemcitabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:The Radiation Therapy Oncology Group
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Christopher H. Crane
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults